These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22674423)

  • 1. A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion.
    Beasley GM; Sharma K; Wong J; Miller M; Turley RS; Lidsky M; Masoud M; Dewhirst MW; Mosca PJ; Zager JS; Tyler DS
    Cancer; 2012 Dec; 118(24):6136-43. PubMed ID: 22674423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated limb infusion in a series of over 100 infusions: a single-center experience.
    Wong J; Chen YA; Fisher KJ; Zager JS
    Ann Surg Oncol; 2013 Apr; 20(4):1121-7. PubMed ID: 23456376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study.
    Kroon HM; Coventry BJ; Henderson MA; Barbour A; Serpell J; Smithers BM; Thompson JF
    Eur J Surg Oncol; 2019 May; 45(5):832-837. PubMed ID: 30867095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms.
    Turaga KK; Beasley GM; Kane JM; Delman KA; Grobmyer SR; Gonzalez RJ; Letson GD; Cheong D; Tyler DS; Zager JS
    Arch Surg; 2011 Jul; 146(7):870-5. PubMed ID: 21768436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.
    Beasley GM; Caudle A; Petersen RP; McMahon NS; Padussis J; Mosca PJ; Zager JS; Hochwald SN; Grobmyer SR; Delman KA; Andtbacka RH; Noyes RD; Kane JM; Seigler H; Pruitt SK; Ross MI; Tyler DS
    J Am Coll Surg; 2009 May; 208(5):706-15; discussion 715-7. PubMed ID: 19476821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions.
    O'Donoghue C; Perez MC; Mullinax JE; Hardman D; Sileno S; Naqvi SMH; Kim Y; Gonzalez RJ; Zager JS
    Ann Surg Oncol; 2017 Dec; 24(13):3842-3849. PubMed ID: 29019175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion.
    Steinman J; Ariyan C; Rafferty B; Brady MS
    J Surg Oncol; 2014 Apr; 109(5):405-9. PubMed ID: 24318953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis.
    Santillan AA; Delman KA; Beasley GM; Mosca PJ; Hochwald SN; Grobmyer SR; Andtbacka RH; Noyes RD; Kane JM; Ross MI; Tyler DS; Zager JS
    Ann Surg Oncol; 2009 Sep; 16(9):2570-8. PubMed ID: 19543771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of isolated limb infusion in limb threatening extremity sarcomas.
    Vohra NA; Turaga KK; Gonzalez RJ; Conley A; Reed D; Bui MM; Cheong D; Letson DG; Zager JS
    Int J Hyperthermia; 2013; 29(1):1-7. PubMed ID: 23205633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Australian Multicenter Study of Isolated Limb Infusion for Melanoma.
    Kroon HM; Coventry BJ; Giles MH; Henderson MA; Speakman D; Wall M; Barbour A; Serpell J; Paddle P; Coventry AG; Sullivan T; Smithers BM; Thompson JF
    Ann Surg Oncol; 2016 Apr; 23(4):1096-103. PubMed ID: 26581203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study.
    Kenyon-Smith TJ; Kroon HM; Miura JT; Teras J; Beasley GM; Mullen D; Farrow NE; Mosca PJ; Lowe MC; Farley CR; Potdar A; Daou H; Sun J; Farma JM; Henderson MA; Speakman D; Serpell J; Delman KA; Smithers BM; Barbour A; Coventry BJ; Tyler DS; Zager JS; Thompson JF
    Eur J Surg Oncol; 2020 Nov; 46(11):2140-2146. PubMed ID: 32739218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is melphalan dose adjustment according to ideal body weight useful in isolated limb infusion for melanoma?
    Huismans AM; Kroon HM; Haydu LE; Kam PC; Thompson JF
    Ann Surg Oncol; 2012 Sep; 19(9):3050-6. PubMed ID: 22526898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Australian multi-center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma.
    Coventry BJ; Kroon HM; Giles MH; Henderson M; Speakman D; Wall M; Barbour A; Serpell J; Paddle P; Coventry AG; Sullivan T; Smithers BM
    J Surg Oncol; 2014 Jun; 109(8):780-5. PubMed ID: 24634160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma.
    Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.
    Thompson JF; Siebert GA; Anissimov YG; Smithers BM; Doubrovsky A; Anderson CD; Roberts MS
    Br J Cancer; 2001 Jul; 85(2):157-65. PubMed ID: 11461070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.
    Beasley GM; Riboh JC; Augustine CK; Zager JS; Hochwald SN; Grobmyer SR; Peterson B; Royal R; Ross MI; Tyler DS
    J Clin Oncol; 2011 Mar; 29(9):1210-5. PubMed ID: 21343562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.
    Raymond AK; Beasley GM; Broadwater G; Augustine CK; Padussis JC; Turley R; Peterson B; Seigler H; Pruitt SK; Tyler DS
    J Am Coll Surg; 2011 Aug; 213(2):306-16. PubMed ID: 21493111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Isolated Limb Infusion Chemotherapy for Advanced Locoregional Melanoma in Elderly Patients: An Australian Multicenter Study.
    Kroon HM; Coventry BJ; Giles MH; Henderson MA; Speakman D; Wall M; Barbour A; Serpell J; Paddle P; Smithers BM; Thompson JF
    Ann Surg Oncol; 2017 Oct; 24(11):3245-3251. PubMed ID: 28799064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities.
    Chai CY; Deneve JL; Beasley GM; Marzban SS; Chen YA; Rawal B; Grobmyer SR; Hochwald SN; Tyler DS; Zager JS
    Ann Surg Oncol; 2012 May; 19(5):1637-43. PubMed ID: 22143576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.